Partnership evolution includes strategic integration of select Novo Nordisk technologies into Aspect BiosystemsAspect will lead development, manufacturing and commercialisation, and Novo Nordisk will have defined rights to expand its role at a later stage Aspect will integrate select manufacturing and R&D capabilities and expertise from the US and Denmark into its Canada-anchored platform Bagsværd, Denmark and Vancouver, BC, Canada, 20 January 2026 – Novo Nordisk and Aspect Biosystems today announced they a ...